Stem Cell Therapy for Knee Pain: Procedure, Timeline, and Expectations

Chronic knee pain affects tens of millions of adults in the United States and represents one of the most common reasons patients explore regenerative medicine. For many patients, the knee has been the subject of years of physical therapy, anti-inflammatory medications, corticosteroid injections, and sometimes prior surgery, yet the pain persists and function continues to decline. Understanding how stem cell therapy is applied to the knee, what the recovery timeline looks like, and what realistic expectations look like based on the available clinical evidence gives patients the information they need to evaluate whether this approach belongs in their care plan.

Common Causes of Chronic Knee Pain

Osteoarthritis and Cartilage Degradation

Osteoarthritis is the most common form of arthritis and the most frequent underlying cause of chronic knee pain in adults over 45. The knee joint consists of three compartments: the medial compartment between the inner portions of the femur and tibia, the lateral compartment between their outer portions, and the patellofemoral compartment between the kneecap and the femoral groove. Osteoarthritis may affect one, two, or all three compartments.

Articular cartilage, the smooth tissue covering the ends of bones within the joint, absorbs impact and allows the joint surfaces to glide during movement. Cartilage has no blood supply of its own and limited capacity for self-repair. Once damaged or lost, it does not regenerate through normal biological processes at a pace that keeps up with the demands placed on it. The result is progressive joint space narrowing, which appears on X-ray as the distance between the femur and tibia decreases. As the cartilage layer thins, the underlying bone is exposed to greater mechanical stress, leading to subchondral bone changes including sclerosis and bone spur formation.

The synovium, the membrane that lines the joint and produces joint fluid, also becomes inflamed in osteoarthritic joints. This synovial inflammation contributes to the pain and swelling that patients experience, sometimes more than the mechanical changes alone. The resulting environment is one of chronic, self-perpetuating inflammation and structural degradation.

Osteoarthritis of the knee affects an estimated 14 million Americans, and its prevalence increases with age, body weight, and prior joint injury. For many patients, it is a slowly progressive condition that conventional medicine addresses with symptom management rather than biological repair.

Meniscus and Ligament Involvement

The menisci are C-shaped cartilage structures that sit between the femoral and tibial joint surfaces, distributing load across the joint and contributing to stability. Meniscus tears may be acute, resulting from twisting injuries, or degenerative, developing over time as the meniscus tissue weakens with age. Degenerative meniscus tears are very common in adults with knee osteoarthritis and often coexist with cartilage loss rather than causing it independently.

When the meniscus is damaged or partially removed, load distribution across the joint changes. The remaining articular cartilage must absorb forces that the meniscus previously distributed, which accelerates cartilage wear. This connection between meniscus health and cartilage integrity is one reason that knee conditions often involve both structures simultaneously.

Ligament laxity and chronic ligament sprains can also contribute to knee pain and to the progression of joint degeneration. When the stabilizing structures of the knee are compromised, abnormal joint mechanics during movement may concentrate stress on specific cartilage regions, contributing to focal wear patterns.

Why Knee Pain Often Persists After Conservative Care

Nonsteroidal anti-inflammatory drugs (NSAIDs) and physical therapy address pain and function but do not modify the underlying tissue damage that drives osteoarthritis progression. They remain appropriate and effective tools for many patients, particularly in earlier stages of disease. But for patients with more advanced tissue damage, these tools provide diminishing returns over time, particularly as the underlying biology continues to deteriorate.

Cortisone injections provide meaningful short-term relief for many patients by suppressing synovial inflammation. Evidence suggests that repeated cortisone injections may contribute to further cartilage degradation over time, which is why many physicians limit their use. For patients who have received multiple cortisone injections without sustained benefit, this tool has often been exhausted as a management strategy.

When conservative care has provided inadequate sustained relief and the patient is not yet at a stage where joint replacement is the clear appropriate step, the clinical space between inadequate conservative care and surgery is exactly the space that regenerative medicine is designed to address.

How Stem Cell Therapy Is Applied to the Knee

Injection Site and Delivery Method

The primary delivery method for stem cell therapy in knee osteoarthritis is intra-articular injection, meaning the cells are placed within the joint space itself. The intra-articular environment allows the cells to interact directly with the synovial fluid, the cartilage surfaces, and the synovial membrane, which is where the biological effects that research suggests may occur are most relevant.

Approaches to the knee joint for intra-articular injection include the suprapatellar approach, in which the needle enters above the patella into the suprapatellar pouch which communicates directly with the main joint space, and medial or lateral parapatellar approaches, in which the needle enters at the edge of the patellar margin. The choice of approach depends on the patient’s anatomy, the physician’s training, and the imaging guidance being used.

In many cases, the primary intra-articular injection is accompanied by periarticular injections into surrounding tendons, ligaments, or muscle insertion points that are contributing to the patient’s pain. A patient with both knee joint OA and concurrent patellar tendinopathy may receive both an intra-articular injection and a targeted injection to the tendon, though each component is directed by specific clinical indications and imaging assessment.

The volume injected intra-articularly is typically in the range of 3 to 6 milliliters, though this varies with the cell concentration, the preparation approach, and the treating physician’s protocol. Concentration and volume are active areas of clinical research, and no universal standard has been established.

How Imaging Guidance Is Used in Knee Procedures

Ultrasound guidance is the standard for knee intra-articular injections in well-equipped regenerative medicine practices. The knee joint is well-visualized by ultrasound because it is a relatively superficial structure with accessible windows for the transducer.

Using the suprapatellar approach, the physician positions the transducer above the patella in the long axis of the thigh, identifying the suprapatellar recess and the overlying quadriceps tendon. The fluid-containing joint space appears hypoechoic (dark on the ultrasound image) relative to surrounding structures, providing a visual target for needle placement. The physician advances the needle in real time under ultrasound visualization, tracking the echogenic needle tip into the joint space.

Confirmation of intra-articular placement can be achieved by injecting a small volume of saline or local anesthetic and observing its spread within the joint space on the ultrasound image. This spread pattern confirms that the needle is in the correct location before the therapeutic cell product is delivered. This confirmation step is what distinguishes image-guided injection from blind injection in terms of delivery confidence.

What Happens to the Cells After Injection

After intra-articular injection, the cells enter the synovial fluid environment and begin interacting with the joint tissue. Research suggests that mesenchymal stem cells injected into a joint may home to sites of tissue damage through chemokine signaling pathways. The CXCR4 receptor on MSCs and its ligand SDF-1 (stromal cell-derived factor 1), which is upregulated in damaged tissue, represent one mechanism that may guide cells toward areas of active tissue injury.

Once at the site of tissue damage, cells appear to exert much of their effect through paracrine signaling, meaning they secrete growth factors, anti-inflammatory cytokines, and other bioactive molecules that alter the local tissue environment. Growth factors including transforming growth factor-beta, fibroblast growth factor, and vascular endothelial growth factor have been identified in MSC secretomes and are associated with tissue repair and remodeling processes.

Some research suggests that MSCs may also directly contribute to cartilage repair by differentiating into chondrocyte-like cells and integrating into cartilage tissue, though the extent to which this occurs in the clinical intra-articular injection setting versus in laboratory conditions is still being characterized. The paracrine mechanism, rather than direct structural engraftment, is currently the better-supported explanation for the clinical effects observed in patients.

In the first one to two weeks after injection, an initial inflammatory phase may occur as the immune system responds to the injection and as the cells begin interacting with the joint environment. This is normal and expected. During this period, patients may experience increased soreness. Over weeks two through eight, the cellular activity period appears to be most active, with cells secreting their signaling molecules and the tissue environment beginning to shift. Patients who see early improvement during this window tend to report that stiffness reduction precedes pain reduction.

What the Recovery Timeline Looks Like

First Two Weeks: What to Expect

The first two weeks following a knee stem cell injection require specific activity and medication management. Soreness and mild to moderate swelling at the treated knee are expected and normal responses to the procedure. These are not signs of a problem. They reflect the biological activity initiated by the injection.

Most physicians advise against nonsteroidal anti-inflammatory drugs including ibuprofen and naproxen during the recovery period, typically for a minimum of two to four weeks. NSAIDs suppress the inflammatory signaling that regenerative therapy depends on, and their use during the critical early window may reduce the effectiveness of the treatment. Acetaminophen for pain management is typically acceptable, and patients should confirm their specific post-procedure medication guidelines with their treating physician.

Patients are generally able to bear weight on the treated knee as tolerated. Crutches are not typically required for knee procedures unless the patient has other mobility limitations. High-impact activities, including running, jumping, and sports that involve significant knee stress, are restricted during this initial period. Low-impact movement such as walking is generally encouraged rather than restricted, as gentle movement supports joint circulation and tissue remodeling without placing excessive mechanical stress on the treated joint.

Months One Through Three: The Cellular Activity Window

The period from approximately one month through three months following injection is often described as the primary cellular activity window. This is when the paracrine signaling effects of the injected cells are believed to be most active, and when many patients begin noticing functional changes.

Patients often report that stiffness reduction is one of the first changes they notice, typically in the range of four to six weeks. Morning stiffness that previously lasted an hour may shorten to 20 minutes. The range of motion available when first standing from a seated position may improve before overall pain scores change significantly. Pain reduction typically follows functional improvement in many cases, though the sequence varies by individual.

The six-week follow-up visit is an opportunity for the physician to assess the patient’s progress, review any concerns, and determine whether the recovery trajectory looks appropriate. This visit is also the typical starting point for introducing or resuming physical therapy, which complements the biological effects of treatment by restoring strength and movement patterns around the treated joint.

When Patients Typically Assess Results

The three-month mark is often described as the earliest point at which a meaningful assessment of treatment response can be made. Some patients show clear improvement by then. Others are still in the trajectory of ongoing improvement at three months and will continue to see changes through six to twelve months.

Clinical research on MSC injection for knee osteoarthritis has generally used six-month and twelve-month outcome assessments as primary evaluation timepoints. Studies published in 2023 and 2024, including systematic reviews covering hundreds of patients across multiple trials, consistently show that meaningful proportions of patients who received stem cell injections for KL Grade 1 to 3 knee OA report improvements in pain scores and functional outcome measures at these timepoints compared to baseline. The magnitude of improvement varies across studies and individual patients, and the field continues to work toward better identification of which patient profiles tend to respond most consistently.

Outcome measurement tools commonly used in clinical practice and research include the Visual Analog Scale for pain, the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and the Knee Injury and Osteoarthritis Outcome Score (KOOS). Patients may encounter these instruments at follow-up visits, as they allow for standardized, quantitative tracking of change over time.

Realistic Expectations for Knee Cases

Mild to Moderate Knee OA: Where Outcomes Tend to Be Positive

The patient population most consistently supported by current clinical evidence is those with mild to moderate knee osteoarthritis, corresponding to Kellgren-Lawrence grades 1 through 3. A 2023 systematic review covering 12 articles, 539 patients, and 576 knees treated with single intra-articular MSC injections for KL Grade 1 to 3 OA found that outcomes improved across patient-reported measures including pain, function, and quality of life, with the authors concluding that this approach represents a safe and reliable treatment option for this population.

Multiple meta-analyses published between 2023 and 2025 covering 8 to 16 randomized controlled trials involving hundreds of patients have found that MSC injections are associated with improvements in pain and function at 6 to 12 months. These are aggregate findings with meaningful variability across individual trials, and the quality of the evidence varies. Patients considering knee stem cell therapy should understand that the evidence is encouraging but not yet at the level of certainty that characterizes interventions with decades of large randomized controlled trial data behind them.

PRP outcomes data provides an additional reference point. Platelet-rich plasma injections for knee osteoarthritis have been studied more extensively and in larger trials, with generally favorable results for pain and function in mild to moderate OA. In many clinics, PRP is considered a first-line regenerative option for earlier-stage OA, with stem cell therapy offered for more advanced cases within the mild-to-moderate range or for patients who have not responded adequately to PRP.

Grade 3 vs. Grade 4 Damage: Where Stem Cell Therapy Has Structural Limits

Kellgren-Lawrence grade 3 represents a clinically important transition zone. Patients at the less severe end of grade 3 retain meaningful cartilage and may respond well to regenerative treatment. Patients at the more severe end of grade 3, where significant joint space narrowing has occurred and MRI shows advanced cartilage thinning, present a more complex picture that requires careful individual assessment.

The determining factor is often how much cartilage remains visible on MRI rather than what the X-ray grade suggests, because X-ray and MRI do not always correlate precisely in terms of actual tissue status. A physician who reviews both plain radiographs and MRI before making a candidacy determination provides a more complete structural assessment than one who relies on X-ray grading alone.

Grade 4 osteoarthritis, characterized by bone-on-bone contact and the near or complete loss of articular cartilage, is where the biological rationale for regenerative therapy encounters a structural limit. When there is no cartilage to repair, the tissue environment that stem cell paracrine signaling targets does not exist in the same form. Some grade 4 patients may report symptom relief from anti-inflammatory effects of regenerative injections, but the clinical evidence is less consistent and the benefit-to-investment ratio is lower. For patients at grade 4, the conversation with a regenerative physician should be explicitly honest about these limits, and surgical consultation for total knee arthroplasty assessment is often the most appropriate next step in the care pathway.

Sources

Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. This content is not a substitute for consultation with a qualified, licensed healthcare provider. Regenerative medicine procedures vary in outcomes based on individual health status, condition severity, and other clinical factors. No specific results are guaranteed. Consult a board-certified physician to determine whether any treatment discussed here is appropriate for your situation.